Based on the fact that Gαo has been implicated in the regulation of many signals involved in epilepsy and MDs, it has been proposed that different approaches to therapy for different variants (agonists for LOF and antagonists for GOF mutants) may be a new therapeutic target for patients with GNAO1 variants (9). The gene discussed is GNAO1; the disease is epilepsy.